July 18, 2025

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Biotech with a Potential Upside of 330%

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) has captured the attention of investors, not only for its cutting-edge approach to treating both childhood and adult diseases but..

Simulations Plus, Inc. (SLP) Investor Outlook: Exploring a Potential 183% Upside in Health Information Services

Simulations Plus, Inc. (NASDAQ: SLP), a prominent player in the healthcare sector, specifically within the health information services industry, offers a compelling investment opportunity with a..

Xencor, Inc. (XNCR): Analyst Consensus and 210% Upside Potential

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company headquartered in Pasadena, California, is capturing investor attention with a striking potential upside of 210.92%. This figure emerges..

Taysha Gene Therapies (TSHA) Stock Analysis: Exploring a 222% Upside Potential with Strong Buy Ratings

Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage biotechnology company, has been capturing investor attention with its ambitious pipeline in the burgeoning field of gene therapy...

Syndax Pharmaceuticals, Inc. (SNDX) Investor Outlook: A Biotech Stock with 253% Potential Upside

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX), a dynamic player in the biotechnology industry, has been capturing investor interest due to its promising pipeline of cancer therapies and..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Exploring a 46.54% Potential Upside in the Biotech Sector

Maze Therapeutics, Inc. (NASDAQ: MAZE) is making waves in the biotechnology sector with its innovative approach to developing small molecule precision medicines. As a clinical-stage biopharmaceutical..

Zenas BioPharma, Inc. (ZBIO) Investor Outlook: Exploring a Potential 143.88% Upside

Zenas BioPharma, Inc. (NASDAQ: ZBIO), a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, is catching the attention of investors with its promising pipeline of immunology-based therapies...

Altimmune, Inc. (ALT) Stock Analysis: Exploring a 409% Potential Upside with Pemvidutide Developments

For investors eyeing opportunities in the biotechnology sector, Altimmune, Inc. (NASDAQ: ALT) offers a compelling narrative. With a market capitalization of $328.48 million and a current..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Exploring a 43% Potential Upside in Biotech

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) stands at a compelling juncture in the biotech sector, especially for investors seeking exposure to groundbreaking developments in neurodegenerative disease treatments...

Bioventus Inc. (BVS) Stock Analysis: Navigating a 90% Potential Upside in the Healthcare Sector

Bioventus Inc. (NASDAQ: BVS) has carved out a niche in the healthcare sector, focusing on medical devices designed to alleviate pain and enhance musculoskeletal therapies. With..

Nutex Health Inc. (NUTX) Stock Analysis: A Potential 124% Upside in the Healthcare Sector

Nutex Health Inc. (NUTX), a Houston-based healthcare service provider, has captured investor attention with its significant potential upside. The company, operating in the thriving healthcare sector,..

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating the Challenges and Opportunities in Healthcare Devices

Avanos Medical, Inc. (NYSE: AVNS), a prominent player in the healthcare sector, operates in the medical devices industry with a focus on innovative solutions that target..

Cullinan Therapeutics, Inc. (CGEM): Investor Outlook with a Potential Upside of 245.88%

Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a burgeoning entity in the biotechnology sector, has recently caught the attention of investors, offering a staggering potential upside of 245.88%...

Upstream Bio, Inc. (UPB) Stock Analysis: A 349.88% Potential Upside in the Biotech Arena

Upstream Bio, Inc. (UPB) is emerging as a compelling prospect for investors seeking opportunities in the healthcare sector, specifically within biotechnology. Despite its current challenges, the..

Opthea Limited (OPT) Stock Analysis: Navigating Challenges in Biotech with a $524.82 Million Market Cap

Opthea Limited (ASX: OPT), an Australian biotechnology firm, stands at the forefront of the healthcare sector with its innovative approach to treating eye diseases. With a..

Sana Biotechnology (SANA) Stock Analysis: A Look at Its 109.74% Potential Upside in the Biotech Sector

Sana Biotechnology, Inc. (NASDAQ: SANA) is drawing attention in the biotechnology sector for its ambitious approach to developing engineered cells as medicines. With a market capitalization..

Arvinas, Inc. (ARVN) Stock Analysis: A Biotech Innovator with a 149.50% Potential Upside

Arvinas, Inc. (NASDAQ: ARVN), a pioneering biotechnology company, is attracting significant interest from investors, driven by its innovative approach to disease treatment and the potential for..

OrthoPediatrics Corp. (KIDS) Stock Analysis: 60.83% Potential Upside in the Pediatric Orthopedic Market

OrthoPediatrics Corp. (NASDAQ: KIDS) is a unique player in the healthcare sector, specializing in medical devices tailored for pediatric orthopedic conditions. With a market capitalization of..

Orthofix Medical Inc. (OFIX) Stock Analysis: Unpacking a 105% Potential Upside for Investors

Orthofix Medical Inc. (NASDAQ: OFIX), a key player in the healthcare sector with a focus on medical devices, is capturing investor attention with its substantial potential..

RxSight, Inc. (RXST) Stock Analysis: Eyeing a Potential 187% Upside with Innovative Medical Devices

RxSight, Inc. (NASDAQ: RXST), a pioneering name in the medical devices industry, is capturing investor attention with its robust potential upside and innovative solutions in the..

Search

Funds

July 18, 2025

Search

Funds

July 18, 2025

FTSE 100

Funds